Generalizable AI predicts immunotherapy outcomes across cancers and treatments
Wanxiang Shen / nature - Nature Medicine, Published online: 03 July 2026; doi:10.1038/s41591-026-04502-7COMPASS is a pan-cancer foundation model that predicts immunotherapy response, across cancer types and treatments, from bulk tumor transcriptomes.
AI Summary: Researchers unveiled a generalizable AI tool that predicts which patients will respond to immunotherapy across multiple cancer types and treatment regimens. By integrating diverse clinical and molecular data, the model helps stratify likely responders and could reduce exposure to costly, ineffective checkpoint therapy—promising smarter patient selection, faster trials, and fewer frustrated oncologists.
- COMPASS paper: pan-cancer AI predicts immunotherapy response (3)
- Researchers and clinicians react on social media (3)
- All Other Stories
COMPASS paper: pan-cancer AI predicts immunotherapy response
Researchers and clinicians react on social media
All Other Stories
The US is hooked on unregulated peptides. But are they effective, or even safe?
livescience - The world of peptides has exploded in wellness circles, but the benefits of injecting these gray-market molecules rest on little clinical evidence.
AI Summary: Unregulated peptide products have proliferated in the US, raising safety and efficacy concerns as federal regulators convene a contentious panel that includes proponents of these off‑label compounds. The debate highlights a market gap where hype often outpaces evidence — and where regulators must decide whether to tidy up the wild west or watch it fester.
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
Stephanie Gomez / nature - Nature Medicine, Published online: 30 June 2026; doi:10.1038/s41591-026-04449-9In the phase 1 ReMIND trial of tumor-associated antigen-specific T cells in patients with pediatric central nervous system tumors, treatment was generally well tolerated with o…
AI Summary: A phase I trial of multi‑antigen‑targeted T cells for aggressive pediatric CNS tumors reported early survival and safety signals, suggesting these engineered cells can engage heterogeneous tumor antigens. Investigators emphasize cautious optimism: encouraging early responses in a dire setting, but longer follow‑up and larger cohorts are needed before this becomes standard‑of‑care.
CheckMate 214 Updates: Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced RCC
oncodaily - First-line treatment for advanced renal cell carcinoma has changed substantially with the use of immune checkpoint inhibitor-based regimens. Long-term follow-up is important to show whether these early survival and response […]
AI Summary: Long‑term CheckMate‑214 data comparing nivolumab plus ipilimumab against sunitinib in advanced renal cell carcinoma show sustained survival benefits for the immunotherapy combination at nine years. The follow‑up reinforces durable responses in a defined subgroup, helping clinicians refine long‑term treatment sequencing and expectations for metastatic RCC.
EMERALD-3 at ESMO GI 2026: Tremelimumab Plus Durvalumab With or Without Lenvatinib Plus TACE in Embolisation-Eligible HCC
oncodaily - In the Proffered Paper session, Joseph P. Erinjeri from New York, United States, presented updated tumour response analyses from the phase III EMERALD-3 study. The abstract, titled “Tumour response analyses […]
AI Summary: EMERALD‑3, presented at ESMO GI 2026, evaluates tremelimumab plus durvalumab with or without lenvatinib and TACE in embolisation‑eligible hepatocellular carcinoma. The trial probes whether adding systemic immunotherapy to locoregional strategies improves outcomes for patients traditionally steered toward embolisation, potentially redefining combination approaches in intermediate‑stage HCC.
Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine
Frank Vinluan / medcitynews - FDA approval of Orca Bio’s Tregzi makes it the first cell therapy based on regulatory T cells, or Tregs. Clinical trial results showed reduced risk of graft-versus-host disease, a common complication of the allogeneic stem cell transplants that are a stan…
AI Summary: Orca Bio’s off‑the‑shelf allogeneic cell therapy received FDA approval, marking a milestone for engineered living medicines. Regulators cleared the product after pivotal efficacy and manufacturing data, offering broader access to cellular therapy but spotlighting cost, supply logistics and the need for robust post‑market safety surveillance.
'Polypill' for heart failure cuts hospitalizations and ER visits by 60% in trial
medicalxpress - A "polypill" combining three medications recommended to treat heart failure into a single daily dose proved far more effective for patients than taking the drugs separately, a randomized clinical trial led by UT Southwestern Medical Center researchers sho…
AI Summary: The POLY‑HF randomized trial found that a fixed‑dose 'polypill' for heart failure with reduced ejection fraction cut hospitalizations and emergency visits by roughly 60%, improving adherence and standardizing therapy. Results suggest a pragmatic, low‑complexity intervention could deliver substantial health‑system benefits if adopted broadly and monitored for implementation challenges.